Regulatory Perspective for Biologics License Application of Recombinant Adeno-Associated Virus Products in China
Human Gene Therapy · 2026
DOI: 10.1177/10430342251393707 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Human Gene Therapy, 2026. Verfasst von Jing Cui und 5 weiteren Autor:innen. Beteiligte Einrichtung: Center for Drug Evaluation, National Medical Products Administration (CDE, NMPA), Beijing, China. Hauptthemen laut MEDLINE: Dependovirus, Genetic Vectors, Genetic Therapy, Biological Products. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: State Key Laboratory of Drug Regulatory Science Project.
Abstract (Originalsprache)
Recombinant adeno-associated virus (rAAV) vectors have emerged as a leading viral vector for in vivo gene therapy because they offer significant advantages over other viral vectors, such as stable physicochemical properties, low pathogenicity, low integration risk, and long-term expression of the transgene. In recent years, the number of rAAV products that have received approval for commercial marketing and clinical trials has grown rapidly, bringing hope for the treatment of refractory and rare diseases. However, rAAV products are highly innovative and complex, and the manufacturing processes to produce them are diverse and rapidly improving. Concurrently, the quality control methodologies and technologies are rapidly advancing and evolving. As biotechnology rapidly advances, there is a heightened need for communication between regulatory authorities and entities applying for rAAV products to be used for in-human trials or commercial marketing. Here, we focus on the discussion of chemistry, manufacturing, and control issues such as the control of adventitious viruses in different manufacturing processes and quality control during the biologics license application of rAAV products. It is expected to provide references and suggestions for the manufacturing and quality control of rAAV vectors, thereby accelerating the high-quality development of gene therapy products.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Drug Evaluation, National Medical Products Administration (CDE, NMPA), Beijing, China.
- State Key Laboratory of Drug Regulatory Science, Beijing, China.
Förderung
- State Key Laboratory of Drug Regulatory Science Project
Zitieren
APA
Cui, J., Wang, W., Liu, D., Han, D., Jin, X., & Wei, W. (2026). Regulatory Perspective for Biologics License Application of Recombinant Adeno-Associated Virus Products in China. Human Gene Therapy. https://doi.org/10.1177/10430342251393707
Vancouver
Cui J, Wang W, Liu D, Han D, Jin X, Wei W. Regulatory Perspective for Biologics License Application of Recombinant Adeno-Associated Virus Products in China. Human Gene Therapy. 2026. doi:10.1177/10430342251393707
BibTeX
@article{Cui2026,
author = {Cui, Jing and Wang, Wenbo and Liu, Dan and Han, Dongmei and Jin, Xiangwaner and Wei, Wei},
title = {Regulatory Perspective for Biologics License Application of Recombinant Adeno-Associated Virus Products in China},
journal = {Human Gene Therapy},
year = {2026},
doi = {10.1177/10430342251393707}
}
EUVIMED